Key Summary Points {#FPar1}
==================

**Why carry out this study?**Diabetic retinopathy (DR) is one of the most important complications of diabetes in a country like Iran which has a high incidence of type 2 diabetes, and it can place a heavy economic burden to the healthcare system. Diabetic macular ischemia (DMI), a category of DR, can cause severe visual loss.Clinically, DMI can be defined by microvascular nonperfusion in the macular region that can be detected by optical coherence tomography angiography (OCTA).Our aim was to assess whether diabetic nephropathy as an indication of diabetic severity is correlated with increased macular nonperfusion.**What was learned from the study?**In patients with retinopathy, the surface area of the foveal avascular zone was significantly larger in those with diabetic nephropathy than in those without diabetic nephropathy.Patients with diabetic nephropathy are more susceptible to DMI.

Introduction {#Sec1}
============

Diabetes mellitus is a global health concern, affecting more than 422 million people worldwide according to the most recent World Health Organization Global Report on Diabetes \[[@CR1]\]. Approximately 25% of people with DM have some degree of diabetic retinopathy (DR) \[[@CR2]\]. Visual loss in people with diabetes is mostly caused by three etiologies: diabetic macular edema (DME), complications of retinal neovascularization (vitreous hemorrhage and retinal detachment), and diabetic macular ischemia (DMI) \[[@CR3], [@CR4]\].

DMI is an important category of DR which leads to severe visual loss. It is characterized by occlusion and atrophy of the retinal capillaries in the macula, accompanied by the narrowing or obliteration of precapillary arterioles, and it affects approximately 7% of patients with DR \[[@CR3]\]. Clinically, it is defined by an enlargement of the foveal avascular zone (FAZ) and paramacular areas of the capillary dropout \[[@CR5]\]. The retinal vasculature is mainly comprised of two inter-connected capillary plexuses: the superficial capillary plexus (SCP) and deep capillary plexus (DCP). The DCP is probably the most important provider of blood supply to the central macula, including the photoreceptors \[[@CR6]\].

The gold standard modality for the measurement of retinal microvasculature remains fluorescein angiography (FA). However, this diagnostic procedure has two major disadvantages: it is a time-consuming and invasive modality that requires venipuncture and dye infusion, and it only provides two-dimensional images \[[@CR5], [@CR6]\]. A recently developed noninvasive technology using optical coherence tomography angiography (OCTA) enables a faster acquisition of retinal vasculature via motion contrast imaging and provides highly detailed three-dimensional images without the need for any contrast fluid \[[@CR5], [@CR7], [@CR8]\]. Studies of diabetic patients using OCTA indicated enlargement and irregularity of the vascular arcades of the FAZ and visible areas of reduced capillary density \[[@CR9], [@CR10]\].

Studies have shown that the presence of structural changes in the retinal microvasculature is associated with diabetic nephropathy (DN) and decreased renal function \[[@CR11]--[@CR13]\]. Diabetic patients with either micro- or clinical albuminuria frequently present with vision-threatening DR \[[@CR14]\].

Although previous studies using OCTA have described abnormalities in the FAZ in patients with various retinal diseases, these studies did not provide information on the systemic conditions that may confound the vascular perfusion \[[@CR15], [@CR16]\]. Therefore, the aim of this study was to assess the macular microvascular abnormality using OCTA by measuring the FAZ area as an indication for the diagnosis and quantification of DMI in patients with DR with or without overt nephropathy.

Methods {#Sec2}
=======

This prospective case--control study was performed between 1 February 2018 and 30 August 2018. Patients with type 2 diabetes for \> 10 years who had DR were included. These patients ranged in age from 30 to 70 years. Exclusion criteria were: poorly controlled hypertension \[systolic blood pressure (SBP) ≥ 180 mmHg or diastolic blood pressure (DBP) ≥ 110 mmHg\]; pregnancy or breastfeeding; history of vitreoretinal surgery; history of macular grid lasering; media opacities obscuring retinal imaging and/or obstacle visualization of the FAZ; epimacular membrane; macular hole; underlying systemic diseases, such as rheumatologic disorders and malignancies, treated or not with chemotherapy.

The patients were divided into two groups, namely, those with overt nephropathy and those without overt nephropathy, based on the presence or absence of gross albuminuria (≥ 300 mg/L per 24 h). Data on age, sex, height, weight, duration of diabetes, the presence of hypertension, and laboratory test results, including glycated hemoglobin (HbA1c), serum albumin, and creatinine, were also collected.

Diabetic retinopathy was graded according to the International Diabetic Retinopathy Severity Scale by experienced ophthalmologists \[[@CR17], [@CR18]\].

Urine albumin was measured by 24-h urine collection. Serum creatinine (Scr) was standardized with calibration traceable to an isotope-dilution mass spectrometry reference measurement procedure, and the estimated glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease (MDRD) equation (175 ×  Scr^−\ 1.154^ ×  age^--\ 0.203^ \[× 0.742, if female\]).

Comprehensive ophthalmologic examinations were performed. These included best-corrected visual acuity (BCVA) measurements using a standard vision chart, with the results recorded as the logarithmic minimum angle of resolution (LogMAR); slit-lamp biomicroscopy; spectral-domain optical coherence tomography (OCT) for retinal nerve fiber layer (RNFL) thickness; average thickness within the inner ring defined as the central foveal subfield (CSF) thickness assessment; and DME. A full and precise dilated fundus examination was performed, and OCTA results were used to assess macular nonperfusion.

The superficial, deep, and full retina FAZ areas in the macular region were evaluated (expressed in mm^2^). The superficial FAZ area is located 3 µm beneath the internal limiting membrane and the outer boundary is located at 15 µm beneath the inner plexiform layer. The image of the deep FAZ area was segmented with an inner boundary 15 µm beneath the inner plexiform layer and an outer boundary at 70 µm beneath the inner plexiform layer (OCTA view of SCP, DCP, and full retinal layers are shown in Fig. [1](#Fig1){ref-type="fig"}). The scanning area was captured in en-face 3 × 3-mm image sections. The FAZ was measured using the caliper provided in the AngioPlex OCT angiography system (Carl Zeiss AG, Oberkochen, Germany) by two experienced examiners. The diameter of the FAZ was measured from the innermost visible well-defined vascular marking from one end to the other both horizontally and vertically. The quantification of macular nonperfusion in OCTA captured images was completed using ImageJ 1.48 software.Fig. 1Optical coherence tomography angiography (OCTA) images of superficial, deep, and full retina foveal avascular zone (FAZ) areas of eye of a patient with nonproliferative diabetic retinopathy and nephropathy. Left: Capillary scan of a right macula center. 3 × 3-mm superficial retinal layer flow image and 3-mm horizontal B-scan through fovea with segmentation lines outlining the superficial retinal layer. Center: 3 × 3-mm-deep retinal layer flow image and 3-mm horizontal B-scan through fovea with segmentation lines outlining the deep retinal layer. Right: 3 × 3-mm total retinal layer flow image and 3-mm horizontal B-scan through fovea with segmentation lines outlining the total retinal layer. The FAZ appears to be enlarged, with the presence of perifoveal capillary dropout. Caliper measurement of both the horizontal and vertical diameters of the superficial, deep capillary plexus, and total retina areas are illustrated

Statistical analyses were performed using PASW statistics software version 18.0.0 (IBM SPSS Statistics, Armonk, NY, USA). Numbers with percentages and means with standard deviations (SD) were used to express the qualitative and quantitative variables, respectively. Nonparametric analysis of variance for comparing the two groups was used alongside other nonparametric tests. Qualitative variables were compared by the Fisher exact test. *P* value \< 0.05 was considered to be statistically significant.

Approval of this study was granted prior to patient enrollment by the Mazandaran University of Medical Sciences ethics committee (ID: IR.MAZUMS.REC.1398.299). This study was performed according to the tenets of the Declaration of Helsinki of 1964, as revised in 2013. All patients who met the inclusion criteria provided written informed consent before enrollment.

Results {#Sec3}
=======

A total of 46 patients (78 eyes) were enrolled in this study, of whom 22 had overt nephropathy and 24 were without overt nephropathy. The mean (± SD) age of these patients was 58.9 ± 11.4 years, and the mean HbA1c level was 7.9 ± 1.8%.

The baseline demographics and clinical characteristics of the enrolled patients are given in Table [1](#Tab1){ref-type="table"}. There were no statistically significant differences in terms of demographic characteristics between the two groups. However, patients with overt nephropathy had significantly higher SBP and DBP (*P* = 0.001 and *P* = 0.005, respectively). Table [1](#Tab1){ref-type="table"} also indicates that a higher level of proteinuria in nephropathic patients compared to those without overt nephropathy (6501 ± 3015 vs. 273 ± 183 mg/24 h) could yield reasonable information regarding significantly lower serum albumin in the former compared with the latter (2.96 ± 0.87 vs. 3.75 ± 0.55 g/dL).Table 1Demographic and clinical characteristics of patients enrolled in the studyVariablesDR with overt nephropathy (*n* = 22 patients)DR without overt nephropathy (*n* = 24 patients)*P* valueDemographic variables Age (years)59.81 ± 9.8458.25 ± 9.740.590 Sex (male/female)12/1013/110.607 BMI (kg/m^2^)25.82 ± 2.4625.58 ± 2.730.754Clinical and laboratory variables Systolic blood pressure (mmHg)148.64 ± 5.39137.08 ± 14.060.001 Diastolic blood pressure (mmHg)86.14 ± 4.8680.83 ± 7.020.005 Duration of diabetes (years)23.77 ± 3.6822.96 ± 3.690.458 HbA1c level (%)8.19 ± 1.087.96 ± 1.030.468 Estimated GFR (mL/min)44.27 ± 5.5248.29 ± 8.960.077 Creatinine (mg/dL)1.86 ± 0.271.68 ± 0.420.093 Serum albumin (g/dL)2.96 ± 0.873.75 ± 0.55\< 0.001 Urine albumin (mg/24 h)6501 ± 3015273 ± 183\< 0.001*BMI* Body mass index,*DR*diabetic retinopathy, *eGFR* glomerular filtration rate, *HbA1c* glycosylated hemoglobin

The ocular characteristics of the two groups are summarized in Table [2](#Tab2){ref-type="table"}. With the exception of central subfield (CSF), there were no significant differences between patients with overt nephropathy and those without overt nephropathy in terms of the results of the different ophthalmologic examinations. Patients with overt nephropathy were found to have a significantly thicker CSF than with patients without nephropathy (*P* = 0.036).Table 2Ocular characteristics of patients enrolled in the studyVariablesDR with overt nephropathy (*n* = 22 patients)DR without overt nephropathy (*n* = 24 patients)*P* valueOcular examination Eyes examined,*n* (right/left)20/1918/210.360 BCVA (LogMAR)0.44 ± 0.290.31 ± 0.250.116 IOP (mmHg)15.18 ± 0.8215.25 ± 1.060.810 RNFL thickness (μm)87.23 ± 7.9688.19 ± 9.330.710 CSF thickness (μm)289.73 ± 7.63284.21 ± 9.510.036DR severity (number of eyes)0.905 NPDR2324 PDR,1615 No DME59 DME3430*BCVA* best corrected visual acuity, *CSF* central subfield, *DME* diabetic macular edema, *IOP* intraocular pressure, *LogMAR* logarithmic minimum angle of resolution, *NPDR* nonproliferative diabetic retinopathy, *PDR* proliferative diabetic retinopathy, *RNFL* retinal nerve fiber layer

The nonperfusion status of the FAZ area on the OCTA images in DR is given in Table [3](#Tab3){ref-type="table"}. In all eyes, the full retinal FAZ sizes were larger in the eyes of patients with overt nephropathy than in those without (*P* = 0.001). In addition, the mean FAZ area on OCTA angiogram images at the level of both the SCP and DCP was significantly larger in patients with overt nephropathy than in those without (*P* = 0.007 and *P* = 0.002, respectively) (Fig. [2](#Fig2){ref-type="fig"}).Table 3Foveal avascular zone area as assessed by optical coherence tomography angiographyFAZ measures (mm^2^)DR with overt nephropathyDR without overt nephropathy*P* valueSuperficial retinal capillary plexus0.484 ± 0.0530.446 ± 0.0360.007Deep retinal capillary plexus0.498 ± 0.0530.454 ± 0.0350.002Full retina0.501 ± 0.0520.456 ± 0.0360.001Values in tables are presented as the mean ± standard deviation*FAZ* Foveal avascular zoneFig. 2Box plot showing FAZ area measurements using OCTA in patients with and without diabetic overt nephropathy.*DCP* Deep retinal capillary plexus,*SCP* superficial retinal capillary plexus

The correlation between either mean SBP or DBP and FAZ size was not statistically significant among groups (FAZ surface and mean SBP, *P* = 0.903; FAZ deep; *P* = 0.990; FAZ full, *P* = 0.963; FAZ surface and mean DBP, *P* = 0.978; FAZ deep, *P* = 0.796; FAZ full, *P* = 0.824).

The correlation between mean serum albumin and FAZ size was also not statistically significant among groups (FAZ surface, *P* = 0.270; FAZ deep, *P* = 0.415; FAZ full, *P* = 0.426).

Discussion {#Sec4}
==========

As mentioned earlier, in recent years FA has been utilized to assess DMI. FA can reveal the vascular mapping of the retina as well as the leakages caused by microaneurysms; therefore, it remains the gold standard modality for the diagnosis and management of DR. Nevertheless, the invasiveness and probable side effects of fluorescein injection always have to be taken into consideration, especially in patients with nephropathy \[[@CR15]\]. A well-known feature of DR in FA is a significant enlargement of FAZ size \[[@CR19], [@CR20]\]. OCTA is a noninvasive diagnostic method that can provide information about retinal capillary microvasculature within specific layers. This modality has shown a wide range of clinical applications and proved to be a suitable diagnosing alternative for many eye conditions, such as glaucoma, exudative age-related macular degeneration, as well as DR \[[@CR15]\].

DN, as the primary cause of chronic kidney disease, leads to 40% of all new cases of end-stage renal disease annually. Overt nephropathy presents with clinical albuminuria, progressive reduction in GFR, and increases in blood pressure \[[@CR21]\]. In addition, diabetic patients with clinical albuminuria are at risk of developing vision-threatening DR \[[@CR14], [@CR22]\].

In this case--control study, we described the application of OCTA to study patients with DR and examine the effect of nephropathy as a systemic metabolic and vascular risk factor. We observed that the FAZ parameters of OCTA among diabetic patients were significantly larger in patients with overt nephropathy than in those without overt nephropathy. To our knowledge, this is the first study to investigate the effect of nephropathy as an indication of diabetes severity on changes in FAZ area in patients with DR.

Our findings could explain the observed functional and structural changes in the retinal microvasculature, demonstrating that patients with overt nephropathy carry an elevated risk of DMI, which can be explained by macular capillary nonperfusion in the presence of clinical albuminuria. In this study, we performed a detailed quantitative analysis of the FAZ surface to assess foveal perfusion disturbance in patients with overt nephropathy using OCTA. A statistically significant difference was observed between the two patient groups (those with overt nephropathy and those without) for each FAZ surface parameter (superficial, deep, and full retina). These results are in agreement with those of other studies which evaluated the reliability of FAZ measurements using OCTA as a marker of diabetic microvascular changes \[[@CR23]--[@CR26]\]. Similar to the pathogenesis of DMI, the progression of nephropathy is ultimately associated with capillary nonperfusion, which leads to podocyte death, neoangiogenesis of the glomerular capillaries, and loss of capillaries in the glomerulus and interstitium. Therefore, our results emphasize the pivotal role that endothelial hypoxia plays in decreasing the GFR in patients with DN \[[@CR27], [@CR28]\].

As in previous studies, we found that eyes with DR and DME had increased FAZ area and reduced vessel density, as shown in the OCTA images, compared to those with DR without DME \[[@CR9], [@CR29]\]. Also, the OCTA images showed that cystic spaces are surrounded by capillary nonperfusion, which shows no evidence of reperfusion after the resolution of DME, suggesting that DME might preferentially develop in areas of ischemia \[[@CR30]\]. Based on the results of other studies, the development of DR but not DME was correlated with a reduction in GFR \[[@CR31]\]. Jeng et al. illustrated that the incidences of nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, and DME increased with time in patients with DN, who also presented a higher rate of DR development than did patients without DN \[[@CR32]\].

Regarding blood pressure, our results show that patients with higher blood pressure had a significant enlargement of FAZ size compared with patients with lower blood pressure. This result is partly consistent with the findings reported in earlier studies indicating that increased blood pressure is a major risk factor for DR progression \[[@CR33]\]. The most interesting result obtained in our study was that the frequency of DME development did not differ between patients in the two different patient groups regardless of blood pressure status. However, patients with significantly higher blood pressure still showed an increased risk of developing perifoveal capillary dropout compared to patients with lower blood pressure. Although a number of studies have suggested that hypertension is associated with DR, some longitudinal data, such as data from the United Kingdom Prospective Diabetes Study (UKPDS) and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), have still been inconsistent \[[@CR34]--[@CR37]\]. Nonetheless, no association has been found for the presence or absence of hypertension and DR in patients with type 2 diabetes \[[@CR37]\]. It has been postulated that hypertension independent of hyperglycemia affects DR through impaired retinal autoregulation, which in turn upregulates the expression of vascular endothelial growth factor (VEGF) in retinal endothelial cells and leads to progressive alterations in the retinal microvasculature, vasopermeability, and areas of retinal occlusion \[[@CR38]\].

There are a number of limitations to this study, including the small sample size, the study design (OCTA was not compared with FA), and the issue of the automated preset in the software of the AngioPlex OCT angiography system with its limited computing of OCTA imaging. Despite the small sample size, we only included eyes with DR which previously had not received any sort of treatment. Therefore, any changes in microvasculature in eyes that had been formerly treated and possibly not to be due to the natural course of the disease were not included in the analysis and would not affect the OCTA parameters. This exclusion of previously treated eyes can be regarded as a strength of this study. Furthermore, since the injection of dye is nephrotoxic, the significance of a comparison between the OCTA FAZ area FA results could be considered arguable. Although our findings have been fully validated both qualitatively and quantitatively with careful measures and statistical models, additional studies are needed to improve clinical practice and reduce the indications for the use of FA.

Conclusion {#Sec5}
==========

The results of this study show that OCTA may provide more detailed images than FA to explore both SCP and DCP in DR. This noninvasive technique offers improved quantification of the FAZ surface in diabetic patients as observed during progression of DR. All patients with DR showed significant changes in FAZ area on OCTA images, and these changes were especially more prominent in eyes of patients with overt nephropathy.

Different etiologies tend to exhibit similar trends in ocular parameter changes in DR. However, the process of excess body protein loss and metabolic waste may affect retinal microcirculation and cause more impaired macular perfusion that can be measured by OCTA and detected as FAZ size measurement. More importantly, we showed that renal impairment as a systemic metabolic and vascular risk factor was associated with enlarged FAZ size in patients with DM.
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